US FDA Grants Orphan Drug Status To Immunomedics’ Trodelvy To Treat Glioblastoma

Immunomedics, a leading biopharmaceutical company, announced that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted Trodelvy (sacituzumab govitecan-hziy) orphan status for the treatment of adult and pediatric patients with glioblastoma.“Glioblastoma is an aggressive cancer with a large unmet need. This orphan drug designation is an important milestone for Immunomedics as we strive to broaden the clinical utility of Trodelvy,” said Dr. Loretta M. Itri, chief medical officer of Immunomedics. “As reported at the recent ESMO Congress, Trodelvy has shown encouraging activity in an early-stage study in brain cancers, including partial responses in small cohorts of patients with brain metastasis from breast cancer and recurrent glioblastoma. We look forward to continuing our evaluation of Trodelvy’s potential to improve the prognosis for this underserved patient population.”Orphan drug status is granted by the FDA to support development of drugs and biologics for underserved patient populations, or rare disorders, that affect fewer than 200,000 people in the US Orphan drug designation qualifies the Company for various development incentives, including tax credits for qualified clinical studies, a waiver of the new drug application fee, and a designated period of market exclusivity following approval.Trodelvy (sacituzumab govitecan-hziy) is the lead product and the most advanced program in Immunomedics’ unique antibody-drug conjugate (ADC) platform. Trodelvy is an ADC that is directed against Trop-2, a cell-surface protein expressed in many solid cancers. Trodelvy binds to Trop-2 and delivers the anti-cancer drug, SN-38, to kill cancer cells. Immunomedics has an extensive development program for Trodelvy, including multiple ongoing studies in triple-negative breast cancer, metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, and metastatic non-small cell lung cancer, either as a monotherapy or in combination with other agents.According to the National Cancer Institute (NCI), an estimated 23,890 American will be diagnosed with brain and other nervous system cancer in 2020 and about 18,020 people will die from the disease in the US this year. Among the numerous brain tumor types, glioblastoma (GBM) is the most aggressive, with median progression-free survival (PFS) and median overall survival (OS) from diagnosis of 6.2-7.5 months and 14.6-16.7 months, respectively, having been reported in clinical trials. For patients with recurrent GBM, chemotherapy regimens are associated with overall response rates of 4-9%, 6-month PFS of 10-19%, and median OS of 5-10 months

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!